Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Adam Cohen, MD
Advertisement
Articles by Adam Cohen, MD
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Advertisement
Latest Updated Articles
What Is Cevostamab’s Mechanism of Action in Multiple Myeloma?Published: December 14th 2025 | Updated:
- Treatment Before Cevostamab May Not Affect Outcomes as Much in Multiple Myeloma
Published: December 13th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer
2
FDA Accepts BLA for Ivonescimab Regimen in Pretreated EGFR-Mutated NSCLC
3
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
4
FDA Clears IND for Investigational Program in Recurrent High-Grade Glioma
5